Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1547-1553

  Finch, Amy P M ^a,c   Lubinski, Jan ⁱ   Møller, Pål ^j   Singer, Christian F ^k   Karlan, Beth ^l   Senter, Leigha ⁿ   Rosen, Barry ^a,b   Maehle, Lovise ^j   Ghadirian, Parviz ^f   Cybulski, Cezary ⁱ   Huzarski, Tomasz ⁱ   Eisen, Andrea ^a,d   Foulkes, William D ^g   Kim Sing, Charmaine ^h   Ainsworth, Peter ^e   Tung, Nadine ^o   Lynch, Henry T ^p   Neuhausen, Susan ^m   Metcalfe, Kelly A ^a   Thompson, Islay ^a,c   Murphy, Joan ^a,b   Sun, Ping ^a,c   Narod, Steven A ^a,c   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e London Regional Cancer Centre   (United States)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ POMERANIAN MEDICAL UNIVERSITY   (Poland)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁿ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^o BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^p CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OCCULT CANCER; OVARIECTOMY; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; QUESTIONNAIRE; RISK REDUCTION; SALPINGOOOPHORECTOMY; UTERINE TUBE CARCINOMA; AGE; EUROPE; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NORTH AMERICA; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; UTERINE TUBE TUMOR; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BRCA2 PROTEIN; EUROPE; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NORTH AMERICA; ODDS RATIO; OVARIAN NEOPLASMS; OVARIECTOMY; PERITONEAL NEOPLASMS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903818387     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.2820     Document Type: Article

References (17)

1. Lancaster JM, Powell CB, Kauff ND, et al: Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 107:159-162, 2007 (Pubitemid 47575743)
2. Finch A, Evans G, Narod SA: BRCA carriers, prophylactic salpingo-oophorectomy and menopause: Clinical management considerations and recommendations. Womens Health (Lond Engl) 8:543-555, 2012
3. Finch A, Metcalfe KA, Chiang JK, et al: The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163-168, 2011
4. Finch A, Beiner M, Lubinski J, et al: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 296:185-192, 2006
5. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010
6. Eisen A, Lubinski J, Klijn J: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 23:7491-7496, 2005 (Pubitemid 46291812)
7. Kotsopoulos J, Lubinski J, Lynch HT, et al: Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 21:1089-1096, 2012
8. Huzarski T, Byrski T, Gronwald J, et al: Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 31:3191-3196, 2013
9. Paley PJ, Swisher EM, Garcia RL, et al: Occult cancer of the fallopian tube in BRCA1 germline mutation carriers at prophylactic oophorectomy: A case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 80:176-180, 2001 (Pubitemid 32158455)
10. Finch A, Shaw P, Rosen B, et al: Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100:58-64, 2006 (Pubitemid 41815050)
11. Olivier RI, van Beurden M, Lubsen MAC, et al: Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 90:1492-1497, 2004 (Pubitemid 38648227)
12. Powell BC, Kenley E, Chen L, et al: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23:127-132, 2005 (Pubitemid 41702631)
13. McLaughlin JR, Rosen B, Moody J, et al: Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst 105:141-148, 2013
14. Rebbeck TR, Friebel T, Wagner T, et al: Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J Clin Oncol 23:7804-7810, 2005 (Pubitemid 46657377)
15. Eisen A, Lubinski J, Gronwald J, et al: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100:1361-1367, 2008
16. Metcalfe KA, Mian N, Enmore M, et al: Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 133:735-740, 2012
17. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008 (Pubitemid 351441190)